OHTOMO, Toshihiko,TANAKA, Takayoshi,SUGITANI, Yasuo,PUIG, Oscar,CHEN, Gong,LEE, Ruey-min,BELOUSOV, Anton,CHEN, Ya-Chi,REIS, Bernhard
申请号：
EP15789676
公开号：
EP3141603A4
申请日:
2015.05.08
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including measuring the number of an immunocyte or an expression level of a molecule expressed on the immunocyte in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the number of an immunocyte or an expression level of a molecule expressed on the immunocyte is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.
